secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001567264-24-000011
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics Q1 net loss $4.6M; cash $10.5M funds operations into Q1 2025
--------------------------------------------------------------------------------

- Net loss of $4.6M in Q1 2024 vs $1.3M in Q1 2023; R&D expenses rose to $2.8M from $0.8M, G&A to $1.9M from $0.5M.
- Cash, cash equivalents and marketable debt securities totaled $10.5M as of Mar 31, 2024; expected to fund operations through Q1 2025.
- Intends to initiate Phase 3 INVINCIBLE-3 Study in mid-2024: INT230-6 monotherapy vs SOC in soft tissue sarcoma, 333 patients, overall survival endpoint.
- Intends to initiate Phase 2/3 INVINCIBLE-4 Study in mid-2024: INT230-6 + SOC in neoadjuvant triple negative breast cancer, endpoint pCR.
- Over 30 sites screened for INVINCIBLE-3; contracts in process; Phase 3 clinical supplies released and shipped.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000156726424000011/0001567264-24-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000156726424000011/intensity-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001567264-24-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer